Novel food: 3-Fucosyllactose produced by a derivative strain of E. coli BL21 (DE3)

Published by AGRINFO on 11 Jan 2023; Revised 06 Aug 2025

Commission Implementing Regulation (EU) 2025/1537 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use of the novel food '3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)'

What is changing and why?

The European Union (EU) is increasing the permitted maximum levels of the novel food 3-Fucosyllactose produced by a derivative strain of *Escherichia coli* BL21 (DE3). This novel food was first authorised under Regulation 2023/52.

The conditions of use have been amended for *E. coli* BL21 (DE3) in infant and follow-on formula, processed cereal-based foods and baby foods for infants and young children, milk-based drinks, and foods for special medical purposes.

The maximum authorised levels of use for this ingredient have been increased to:

- 1.75 g/l in infant formula (up from 0.9 g/l), follow-on formula (up from 0.9 g/l), and foods for special medical purposes for infants and young children (up from 1.2 g/l)
- 4.0 g/day in food supplements intended for the general population, excluding infants and young children (up from 3.0 g/day).

These conditions of use apply only to the company Chr. Hansen A/S, which applied for the initial authorisation.

Timeline

The newly approved conditions of use for this novel food apply from **19 August 2025**.

For more information see the full record on the AGRINFO website – where you can also view the latest AGRINFO Update newsletters and search the database.

available on this website or any link to external sites. The use of the website is at the user's sole risk and responsibility. This information platform was created and maintained with the financial support of the European Union. Its contents do not, however, reflect the views of the European Union.